It is interesting they changed very little of the wording overall but, what they did change from the last filing is very important. Alpharx is always careful with their wording. The previous version was "we may not receive any milestone payments". The fact that they changed it to expecting more payments in the New Year is a small thing, but an important one. They recently mentioned in the Investors conference that Indaflex was going to the FDA regarding late stage trials.Regarding the Pharma company evaluation according to the same investor conference they decided to move ahead with at least one of the products. It also has more than one focus. Q3 and Q4 will be pivotal for these products. The 6 month evaluation is what is unclear. I think that is a non factor since they are already going through trials. - ARX828 iNOS Inhibitor for Inflammation **90% chance of being chosen as candidate for R.A. and I.B.D. This is the product being tested for the TOP 10 PHARMA COMPANY.(estimates $450M payment if phase trials go well)
